These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27749324)

  • 1. Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review.
    Kyriakopoulos CE; Liu G
    Cancer J; 2016; 22(5):322-325. PubMed ID: 27749324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective.
    Teoh JY; Ng CF; Poon DM
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():5-8. PubMed ID: 30489034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should docetaxel be administered earlier in prostate cancer therapy?
    Graff JN; Beer TM
    Expert Rev Anticancer Ther; 2015; 15(9):977-9. PubMed ID: 26223224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upfront Chemotherapy for Metastatic Prostate Cancer.
    Lam ET; Flaig TW
    Oncology (Williston Park); 2015 Dec; 29(12):956-62. PubMed ID: 26676900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
    Ohlmann CH
    Urologe A; 2017 Nov; 56(11):1424-1429. PubMed ID: 28983763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for metastatic castrate-sensitive prostate cancer.
    Miller RE; Sweeney CJ
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
    Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H
    Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
    van Soest RJ; de Wit R
    BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer.
    Ceresoli GL; De Vincenzo F; Sauta MG; Bonomi M; Zucali PA
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):374-80. PubMed ID: 26222275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?
    Damodaran S; Kyriakopoulos CE; Jarrard DF
    Urol Clin North Am; 2017 Nov; 44(4):611-621. PubMed ID: 29107277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.
    Aguiar PN; Barreto CMN; Gutierres BS; Tadokoro H; Lopes GL
    Einstein (Sao Paulo); 2017; 15(3):349-354. PubMed ID: 29091159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
    García de Paredes Esteban JC; Alegre Del Rey EJ; Asensi Díez R
    Farm Hosp; 2017 Jul; 41(4):550-558. PubMed ID: 28683707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
    Amato RJ; Teh BS; Henary H; Khan M; Saxena S
    Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO].
    Ohlmann CH; Gschwend J; Miller K
    Urologe A; 2016 Sep; 55(9):1164-72. PubMed ID: 27431813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early chemohormonal therapy in prostate cancer: preliminary data and randomized trials.
    Petrylak DP
    Curr Oncol Rep; 2003 May; 5(3):229-30. PubMed ID: 12667420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer.
    Shenoy N; Kohli M
    Indian J Urol; 2016; 32(4):257-261. PubMed ID: 27843206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of chemotherapy in the treatment of hormone sensitive metastatic prostate cancer.].
    Pérez-Gracia JL; Diez Caballero F; Gúrpide A; de Fata Chillón FR; Villacampa F
    Arch Esp Urol; 2018 Mar; 71(3):276-280. PubMed ID: 29633948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.